Application Value of Serum Cyclophilin A Combined with Double Low Dose Technique and Echocardiography in the Diagnosis of Acute Myocardial Infarction

Abstract

Background: Cyclophilin A (CyPA) is one of the important members of cyclophilin family and is well known for its biological function. It mediates macrophages to express matrix metalloproteinase (MMPS) through ERK1/2 and I_kB/NF-_kB pathways and provides a basis for inflammatory cell infiltration and migration. This study aims to analyze the value of CyPA combined with double low dose technique and echocardiography in the diagnosis of acute myocardial infarction (AMI). Methods: The clinical data of 63 patients with AMI admitted to Zibo Central Hospital from March 2021 to March 2022 were selected as the lesion group (LG) for retrospective analysis. In contrast, 57 healthy people who underwent physical examination in Zibo Central Hospital during the same period were selected as the control group (CG). In total, 120 research subjects were included in this study. All patients in both groups received double low dose of coronary CT angiography (CCTA) and echocardiography examination. The enzyme-linked immunosorbent assay (ELIZA) was adopted to detect serum CyPA level, and the receiver operating characteristic (ROC) curve was used to analyze the application value of serum CyPA. The double low dose of CCTA combined with echocardiography was used for the diagnosis of AMI. Results: The LG had remarkably lower left ventricular ejection fraction (LVEF) levels and higher serum CyPA, left ventricular end diastolic diameter (LVEDD), and Gensini scores than the CG (p < 0.001). Results of logistic regression analysis showed that serum CyPA, LVEF, Gensini scores, and LVEDD were independent risk factors of AMI. The area under the curve of ROC (AUC) value and Youden indexes of the combined diagnosis of the three were higher than those of each single diagnosis. Conclusions: Serum CyPA combined with double low dose technique and echocardiography had higher clinical values in the diagnosis of AMI, which provides the basis for using it for clinical treatment program.